Investor Relations

Investor Relations

Histogen seeks to redefine regenerative medicine through the development of patented, innovative technologies that stimulate the body’s own stem cells to regenerate tissues, with applications in aesthetic and therapeutic markets. The Company’s novel platform utilizes human proteins and growth factors produced by hypoxia-induced multipotent cells to address what Histogen believes to be underserved, multibillion dollar global markets.